United States Orthobiologics Market Outlook to 2033 - Cartilage Repair, Bone Grafts and Substitutes, Bone Growth Stimulators and Others
Description
United States Orthobiologics Market Outlook to 2033 - Cartilage Repair, Bone Grafts and Substitutes, Bone Growth Stimulators and Others
Summary
GlobalData’s “United States Orthobiologics Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Orthobiologics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cartilage Repair, Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation
The United States Orthobiologics Market report provides key information and data on -
United States Orthobiologics is segmented as follows -
The United States Orthobiologics Market report helps you to develop -
Summary
GlobalData’s “United States Orthobiologics Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Orthobiologics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Cartilage Repair, Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation
The United States Orthobiologics Market report provides key information and data on -
- Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
- 2023 company share data for Orthobiologics Market.
- Global corporate-level profiles of key companies operating within the United States Orthobiologics Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
United States Orthobiologics is segmented as follows -
- Cartilage Repair
- Bone Grafts and Substitutes
- Bone Growth Stimulators
- Soft Tissue Biologics
- Viscosupplementation
The United States Orthobiologics Market report helps you to develop -
- Business strategies by identifying the key market segments poised for strong growth in the future.
- Market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Table of Contents
78 Pages
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Orthobiologics Market Segmentation
- 2.3 Definitions of Markets Covered in the Report
- 3 Orthobiologics Market, United States
- 3.1 Orthobiologics Market, United States, Revenue ($m), 2018-2033
- 3.1.1 Bone Grafts and Substitutes Market, United States, Revenue ($m), by Segment, 2018-2033
- 3.1.2 Bone Growth Stimulators Market, United States, Revenue ($m), by Segment, 2018-2033
- 3.1.3 Cartilage Repair Market, United States, Revenue ($m), by Segment, 2018-2033
- 3.1.4 Soft Tissue Biologics Market, United States, Revenue ($m), by Segment, 2018-2033
- 3.1.5 Viscosupplementation Market, United States, Revenue ($m), by Segment, 2018-2033
- 3.2 Orthobiologics Market, United States, Volume (Units), 2018-2033
- 3.2.1 Bone Grafts and Substitutes Market, United States, Volume (Units), by Segment, 2018-2033
- 3.2.2 Bone Growth Stimulators Market, United States, Volume (Units), by Segment, 2018-2033
- 3.2.3 Cartilage Repair Market, United States, Volume (Units), by Segment, 2018-2033
- 3.2.4 Soft Tissue Biologics Market, United States, Volume (Units), by Segment, 2018-2033
- 3.2.5 Viscosupplementation Market, United States, Volume (Units), by Segment, 2018-2033
- 3.3 Orthobiologics Market, United States, Average Price ($), 2018-2033
- 3.4 Orthobiologics Market, United States, Company Share by Revenue ($m), 2024
- 4 Overview of Key Companies in United States, Orthobiologics Market
- 4.1 Medtronic Plc
- 4.1.1 Company Overview
- 4.2 Sanofi
- 4.2.1 Company Overview
- 4.3 Stryker Corp
- 4.3.1 Company Overview
- 4.4 Bioventus Inc
- 4.4.1 Company Overview
- 4.5 Orthofix Holdings Inc
- 4.5.1 Company Overview
- 4.6 Zimmer Biomet Holdings Inc
- 4.6.1 Company Overview
- 4.7 Orthofix Medical Inc
- 4.7.1 Company Overview
- 4.8 Arthrex Inc
- 4.8.1 Company Overview
- 4.9 Enovis Corp
- 4.9.1 Company Overview
- 5 Orthobiologics Market Pipeline Products
- 6 Financial Deals Landscape
- 6.1 Debt Offerings
- 6.1.1 Zimmer Biomet Holdings Prices USD743.76 Million in Public Offering of 3.518% Notes Due 2032
- 7 Recent Developments
- 7.1 Corporate Communications
- 7.1.1 Jul 08, 2025: Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed
- 7.1.2 May 21, 2025: Medtronic Announces Leadership Change in Cardiovascular Portfolio
- 7.1.3 Aug 21, 2024: AGFA HealthCare Announces the UK AGFA HealthCare User Group
- 7.2 Financial Announcements
- 7.2.1 Apr 18, 2025: Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025
- 7.2.2 Apr 16, 2025: Assure Tech (Hangzhou) Receives CLIA Approval for FaStep Multi-Drug Urine Test Panel
- 7.2.3 Mar 05, 2025: Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
- 7.2.4 Feb 04, 2025: Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
- 7.2.5 Jan 22, 2025: Baxter to Host Fourth-Quarter 2024 Financial Results Conference Call for Investors
- 7.2.6 Jan 13, 2025: ATEC Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook
- 7.2.7 Nov 14, 2024: Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- 7.2.8 Nov 07, 2024: Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
- 7.2.9 Nov 05, 2024: Globus Medical Reports Third Quarter 2024 Results
- 7.2.10 Oct 30, 2024: MIMEDX Reports Q3 2024 Operating and Financial Results
- 7.2.11 Oct 17, 2024: Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
- 7.2.12 Oct 17, 2024: Anika Announces Third Quarter 2024 Results Conference Call Date
- 7.2.13 Oct 17, 2024: Ocugen to Host Conference Call on Friday, November 8 to Discuss Business Updates and Third Quarter 2024 Financial Results
- 7.2.14 Oct 16, 2024: Baxter to Host Third-Quarter 2024 Financial Results Conference Call for Investors
- 7.2.15 Oct 15, 2024: Globus Medical Schedules Third Quarter Earnings Release and Conference Call
- 7.2.16 Oct 09, 2024: Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2024 Financial Results
- 7.2.17 Oct 03, 2024: Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
- 7.2.18 Aug 07, 2024: Zimmer Biomet Announces Second Quarter 2024 Financial Results
- 7.2.19 Aug 01, 2024: Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- 7.2.20 Jul 31, 2024: ATEC Reports Second Quarter 2024 Financial Results And Raises Full-Year Guidance
- 7.3 Government and Public Interest
- 7.3.1 Jun 19, 2025: Mah Sing Healthcare Sdn Bhd Receives 510(K) Clearance For Nitrile Powder Free Examination Glove with Tremella Fuciformis Extract
- 7.3.2 Apr 10, 2025: New Study Shows Arima Genomics’ Technology Detects Actionable Cancer Drivers in Solid Tumors Missed by Standard Tests
- 7.3.3 Feb 17, 2025: Baxter to Present at Raymond James & Associates’ 46th Annual Institutional Investors Conference
- 7.3.4 Feb 04, 2025: Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
- 7.3.5 Dec 18, 2024: Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference
- 7.3.6 Dec 17, 2024: Akava congratulates SAB Chair Dr. Hande, Founder Dr. Richard B. Silverman, and Dr. William on grant to investigate AKV9 in neurodegenerative diseases
- 7.3.7 Dec 09, 2024: ATEC to Present at the 2025 J.P. Morgan Healthcare Conference
- 7.3.8 Nov 12, 2024: Baxter to Present at Stifel 2024 Healthcare Conference
- 7.3.9 Nov 04, 2024: ATEC to Participate in Upcoming Conferences
- 7.3.10 Oct 14, 2024: Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
- 7.3.11 Aug 28, 2024: Baxter to Present at 2024 Wells Fargo Healthcare Conference
- 7.4 Legal And Regulatory
- 7.4.1 Jun 13, 2025: FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber Research
- 7.4.2 Jun 04, 2025: Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
- 7.4.3 Apr 15, 2025: Hangzhou SHINING3D Dental Technology Receives 510(K) Clearance For DT20 Denture Base Resin
- 7.4.4 Jan 05, 2025: Synergy Biomedical Receives 510(K) Clearance For BioSphere Putty
- 7.5 Other Significant Developments
- 7.5.1 May 20, 2025: APEX Biologix Enters Exclusive U.S. Distribution Agreement with Bioventus LLC for XCELL PRP System
- 7.6 Product News
- 7.6.1 Apr 23, 2025: Assure Tech Receives CLIA Approval for Healcare Panel Dip Test
- 7.6.2 Mar 10, 2025: Carmell Corp Rebrands as Longevity Health Holdings To Highlight Business Focus & Growth Strategy
- 7.6.3 Dec 19, 2024: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-001, Its Novel Half-Life Extended Anti-il-23p19 Antibody
- 7.6.4 Oct 24, 2024: A New Method to Enhance Effectiveness of Cartilage Repair Therapy
- 7.7 Strategy And Business Planning
- 7.7.1 Mar 06, 2025: Modern Sports Medicine & Wellness Enters Into Partnership With NeuralCure AI
- 7.7.2 Jan 08, 2025: Moonlake Initiates Three New Clinical Trials and Further Expands the Portfolio of Indications for the Nanobody Sonelokimab
- 8 Appendix
- 8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Benchmarking
- 8.2 GlobalData Consulting
- 8.3 Contact Us
- 8.4 Disclaimer
- List of Tables
- Table 1: Orthobiologics Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 2: Bone Grafts and Substitutes Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 3: Bone Growth Stimulators Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 4: Cartilage Repair Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 5: Soft Tissue Biologics Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 6: Viscosupplementation Market, United States, Revenue ($m), USD Constant, 2018-2033
- Table 7: Orthobiologics Market, United States, Volume (Units), 2018-2033
- Table 8: Bone Grafts and Substitutes Market, United States, Volume (Units), 2018-2033
- Table 9: Bone Growth Stimulators Market, United States, Volume (Units), 2018-2033
- Table 10: Cartilage Repair Market, United States, Volume (Units), 2018-2033
- Table 11: Soft Tissue Biologics Market, United States, Volume (Units), 2018-2033
- Table 12: Viscosupplementation Market, United States, Volume (Units), 2018-2033
- Table 13: Orthobiologics Market, United States, Average Price ($), 2018-2033
- Table 14: Orthobiologics Market, United States, Company Share by Revenue ($m), 2024
- Table 15: Orthobiologics Market Pipeline Products
- Table 16: Zimmer Biomet Holdings Prices USD743.76 Million in Public Offering of 3.518% Notes Due 2032
- Table 17: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country
- List of Figures
- Figure 1: Orthobiologics Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 2: Bone Grafts and Substitutes Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 3: Bone Growth Stimulators Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 4: Cartilage Repair Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 5: Soft Tissue Biologics Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 6: Viscosupplementation Market, United States, Revenue ($m), USD Constant, 2018-2033
- Figure 7: Orthobiologics Market, United States, Volume (Units), 2018-2033
- Figure 8: Bone Grafts and Substitutes Market, United States, Volume (Units), 2018-2033
- Figure 9: Bone Growth Stimulators Market, United States, Volume (Units), 2018-2033
- Figure 10: Cartilage Repair Market, United States, Volume (Units), 2018-2033
- Figure 11: Soft Tissue Biologics Market, United States, Volume (Units), 2018-2033
- Figure 12: Viscosupplementation Market, United States, Volume (Units), 2018-2033
- Figure 13: Orthobiologics Market, United States, Company Share (%), 2024
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
